person · Reporting owner

BIENAIME JEAN JACQUES

Disclosed activity across 6 companies

Tapewire entity: 21586
SEC CIK: 0001221590

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Ascendis Pharma A/SASND · Entity 1628	Director	April 14, 2026	September 28, 2026
IMMUNIC, INC.VTL · Entity 6306	Director	September 24, 2018	September 24, 2018
INCYTE CORPINCY · Entity 3182	Director	June 08, 2026	June 10, 2026
Immunome Inc.IMNM · Entity 4219	Director	June 10, 2026	June 12, 2026
Keros Therapeutics, Inc.KROS · Entity 6242	Director	August 17, 2026	August 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Ascendis Pharma A/S

Report date April 14, 2026 · Filed September 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $172.35 · Expires 2035-06-10	Direct	0	Reported balance After 2026-04-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-04-14 · Disposition to issuer · Disposed 9,160 · Balance 0 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.
WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $249.84 · Expires 2036-04-14	Direct	9,160	Reported balance After 2026-04-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-14 · Grant · Acquired 9,160 · Balance 9,160 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.

Filing footnotes · ownership attribution and instrument terms

F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.

F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer.

F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.

IMMUNIC, INC.

Report date September 24, 2018 · Filed September 24, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,500	Reported balance After 2018-09-24 transaction · row 1 1 source row Row 1 · 2018-09-24 · Sale · Disposed 26,619 · Balance 18,500 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.

INCYTE CORP

Report date June 08, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	24,424	Reported balance After 2026-06-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 24,424 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07	Direct	6,111	Reported balance After 2026-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Filing footnotes · ownership attribution and instrument terms

F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Immunome Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.16 · Expires 2036-06-09	Direct	9,897	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 9,897 · Balance 9,897 F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

Keros Therapeutics, Inc.

Report date August 17, 2026 · Filed August 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	19,592	Reported balance After 2026-08-17 transaction · row 1 1 source row Row 1 · 2026-08-17 · Purchase · Acquired 1,000 · Balance 19,592 F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

BIOMARIN PHARMACEUTICAL INC

Report date May 20, 2024 · Filed May 21, 2024

Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	473,792	Reported balance After 2024-05-20 transaction · row 1 1 source row Row 1 · 2024-05-20 · Tax withholding · Disposed 1,202 · Balance 473,792
Common StockSEC Table I · non-derivative	IndirectShares held by Jean-Jacques Bienaime Family Trust	247,333	Reported balance Holding disclosure · report date 2024-05-20 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 247,333
Common StockSEC Table I · non-derivative	IndirectShares held as UTMA custodian for child 1	100	Reported balance Holding disclosure · report date 2024-05-20 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 100
Common StockSEC Table I · non-derivative	IndirectShares held as UTMA custodian for child 2	100	Reported balance Holding disclosure · report date 2024-05-20 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 100

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 15, 2021 Filed Dec 18, 2021 00:03 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	6,000	$0.00 Strike: $37.46	$0.00	Disclosure SEC source: 0001567619-21-022297 · doc1.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 6,000 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
December 15, 2021 Filed Dec 18, 2021 00:03 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	6,000	$82.71	$496,260.00	Disclosure SEC source: 0001567619-21-022297 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,689 F2 · date: Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. Read SEC document
December 15, 2021 Filed Dec 18, 2021 00:03 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	6,000	$37.46	$224,760.00	Disclosure SEC source: 0001567619-21-022297 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on October 13, 2021. Read SEC document
December 10, 2021 Filed Dec 18, 2021 00:03 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GiftCommon Stock	700	$0.00	$0.00	Disclosure SEC source: 0001567619-21-022297 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,689 F1 · date: On December 10, 2021 the reporting person gifted 700 shares to an educational institution. Read SEC document
December 01, 2021 Filed Dec 3, 2021 02:42 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	1,500	$87.22	$130,831.50	Disclosure SEC source: 0001567619-21-021536 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,389 F1 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's purchase of shares at a price of $78.7700 on September 9, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Read SEC document
October 20, 2021 Filed Oct 22, 2021 20:36 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	1,000	$0.00 Strike: $37.46	$0.00	Disclosure SEC source: 0001567619-21-018613 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,000 Underlying: Common Stock · 1,000 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
October 20, 2021 Filed Oct 22, 2021 20:36 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	1,000	$37.46	$37,460.00	Disclosure SEC source: 0001567619-21-018613 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 09, 2021 Filed Dec 3, 2021 02:42 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	OtherCommon Stock	50	$78.77	$3,938.50	Disclosure SEC source: 0001567619-21-021536 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,889 Read SEC document
June 21, 2021 Filed Jun 23, 2021 21:04 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	1,000	$0.00 Strike: $37.46	$0.00	Disclosure SEC source: 0001567619-21-012534 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,000 Underlying: Common Stock · 1,000 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
June 21, 2021 Filed Jun 23, 2021 21:04 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	1,000	$37.46	$37,460.00	Disclosure SEC source: 0001567619-21-012534 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 26, 2021 Filed May 28, 2021 10:57 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	8,010	$0.00 Strike: $83.16	$0.00	Disclosure SEC source: 0001209191-21-036399 · doc4.xml · derivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,010 Underlying: Common Stock · 8,010 shares Expires 2031-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
May 26, 2021 Filed May 28, 2021 10:57 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,923	$0.00	$0.00	Disclosure SEC source: 0001209191-21-036399 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,844 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
May 10, 2021 Filed May 12, 2021 23:21 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	8,513	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001567619-21-009745 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,513 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
May 10, 2021 Filed May 12, 2021 23:21 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	8,513	$77.29	$657,969.77	Disclosure SEC source: 0001567619-21-009745 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,839 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. Read SEC document
May 10, 2021 Filed May 12, 2021 23:21 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	8,513	$26.49	$225,509.37	Disclosure SEC source: 0001567619-21-009745 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. Read SEC document
May 07, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	25,000	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · derivative · entry 11 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,513 Underlying: Common Stock · 25,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F9 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
May 07, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	3,329	$79.39	$264,302.63	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · nonDerivative · entry 8 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,839 F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F7 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $77.9400 on March 4, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. F8 · price: The price in column 4 is the weighted average price. The price actually received ranged from $79.15 to $79.75. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document
May 07, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	6,115	$78.77	$481,672.44	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · nonDerivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,168 F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F6 · price: The price in column 4 is the weighted average price. The price actually received ranged from $78.15 to $79.14. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document
May 07, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	15,556	$77.60	$1,207,145.60	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · nonDerivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,283 F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F5 · price: The price in column 4 is the weighted average price. The price actually received ranged from $77.13 to $77.95. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document
May 07, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	25,000	$26.49	$662,250.00	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · nonDerivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. Read SEC document
May 06, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	25,000	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · derivative · entry 10 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,513 Underlying: Common Stock · 25,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F9 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
May 06, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	10,175	$78.69	$800,670.75	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,839 F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F4 · price: The price in column 4 is the weighted average price. The price actually received ranged from $78.38 to $78.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document
May 06, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	14,825	$78.01	$1,156,527.90	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,014 F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $77.375 to $78.37. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document
May 06, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	25,000	$26.49	$662,250.00	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. Read SEC document
April 30, 2021 Filed May 4, 2021 00:24 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	1,000	$0.00 Strike: $37.46	$0.00	Disclosure SEC source: 0001567619-21-008885 · doc1.xml · derivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,000 Underlying: Common Stock · 1,000 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
April 30, 2021 Filed May 4, 2021 00:24 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	1,000	$37.46	$37,460.00	Disclosure SEC source: 0001567619-21-008885 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 30, 2021 Filed May 11, 2021 01:07 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	341	$62.41	$21,280.79	Disclosure SEC source: 0001567619-21-009481 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,839 F1 · date: Represents shares acquired by the reporting person on April 30, 2021, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document
April 23, 2021 Filed Apr 27, 2021 00:44 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	10,000	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001567619-21-008607 · doc1.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,513 Underlying: Common Stock · 10,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
April 23, 2021 Filed Apr 27, 2021 00:44 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	10,000	$79.34	$793,400.00	Disclosure SEC source: 0001567619-21-008607 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,498 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F2 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $77.9400 on March 4, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Read SEC document
April 23, 2021 Filed Apr 27, 2021 00:44 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	10,000	$26.49	$264,900.00	Disclosure SEC source: 0001567619-21-008607 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. Read SEC document
April 22, 2021 Filed Apr 27, 2021 00:44 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	10,000	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001567619-21-008607 · doc1.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,513 Underlying: Common Stock · 10,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
April 22, 2021 Filed Apr 27, 2021 00:44 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	10,000	$78.91	$789,100.00	Disclosure SEC source: 0001567619-21-008607 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,498 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. F2 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $77.9400 on March 4, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Read SEC document
April 22, 2021 Filed Apr 27, 2021 00:44 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	10,000	$26.49	$264,900.00	Disclosure SEC source: 0001567619-21-008607 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020, as amended on March 29, 2021. Read SEC document
March 22, 2021 Filed Mar 24, 2021 00:50 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Tax withholdingCommon Stock	5,519	$78.52	$433,351.88	Disclosure SEC source: 0001567619-21-006816 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,498 Read SEC document
March 16, 2021 Filed Mar 18, 2021 01:24 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Tax withholdingCommon Stock	5,559	$77.21	$429,210.39	Disclosure SEC source: 0001567619-21-006546 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,017 Read SEC document
March 15, 2021 Filed Mar 18, 2021 01:24 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantStock Option (Right to buy Common Stock) · Derivative	101,820	$0.00 Strike: $78.39	$0.00	Disclosure SEC source: 0001567619-21-006546 · doc1.xml · derivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,820 Underlying: Common Stock · 101,820 shares Expires 2031-03-14 F1 · date: Restricted stock units granted on March 15, 2021. Price not applicable. F2 · balance_after: Option grant vests 12/48th on March 15, 2022 and 1/48th on the 15th day of each month thereafter. Read SEC document
March 15, 2021 Filed Mar 18, 2021 01:24 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Tax withholdingCommon Stock	23,426	$78.39	$1,836,364.14	Disclosure SEC source: 0001567619-21-006546 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,576 Read SEC document
March 15, 2021 Filed Mar 18, 2021 01:24 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	GrantCommon Stock	41,350	$0.00	$0.00	Disclosure SEC source: 0001567619-21-006546 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,002 F1 · price: Restricted stock units granted on March 15, 2021. Price not applicable. Read SEC document
March 12, 2021 Filed Mar 16, 2021 00:26 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	7,000	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001567619-21-006359 · doc1.xml · derivative · entry 8 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,513 Underlying: Common Stock · 7,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
March 12, 2021 Filed Mar 16, 2021 00:26 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	7,000	$77.10	$539,700.00	Disclosure SEC source: 0001567619-21-006359 · doc1.xml · nonDerivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,652 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document
March 12, 2021 Filed Mar 16, 2021 00:26 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	7,000	$26.49	$185,430.00	Disclosure SEC source: 0001567619-21-006359 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document
March 11, 2021 Filed Mar 16, 2021 00:26 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	7,000	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001567619-21-006359 · doc1.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,513 Underlying: Common Stock · 7,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
March 11, 2021 Filed Mar 16, 2021 00:26 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	7,000	$77.68	$543,760.00	Disclosure SEC source: 0001567619-21-006359 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,652 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document
March 11, 2021 Filed Mar 16, 2021 00:26 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	7,000	$26.49	$185,430.00	Disclosure SEC source: 0001567619-21-006359 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,652 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document
March 04, 2021 Filed Mar 16, 2021 00:26 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	OtherCommon Stock	100	$77.94	$7,794.00	Disclosure SEC source: 0001567619-21-006359 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,652 Read SEC document
February 19, 2021 Filed Feb 23, 2021 01:38 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	7,000	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001567619-21-004619 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,513 Underlying: Common Stock · 7,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
February 19, 2021 Filed Feb 23, 2021 01:38 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	7,000	$83.58	$585,060.00	Disclosure SEC source: 0001567619-21-004619 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,552 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document
February 19, 2021 Filed Feb 23, 2021 01:38 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionCommon Stock	7,000	$26.49	$185,430.00	Disclosure SEC source: 0001567619-21-004619 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document
February 18, 2021 Filed Feb 20, 2021 02:22 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	Exercise / conversionStock Option (Right to buy Common Stock) · Derivative	7,000	$0.00 Strike: $26.49	$0.00	Disclosure SEC source: 0001567619-21-004529 · doc1.xml · derivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,513 Underlying: Common Stock · 7,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document
February 18, 2021 Filed Feb 20, 2021 02:22 UTC	BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404	SaleCommon Stock	7,000	$85.08	$595,560.00	Disclosure SEC source: 0001567619-21-004529 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,552 F1 · date: Trade made pursuant to a 10b5-1 plan executed on December 3, 2020. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.